Cited by 3,063Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Open access

Hellmann, Matthew D., Ciuleanu, Tudor-Eliade, Pluzanski, Adam, Lee, Jong Seok, Otterson, Gregory A., Audigier-Valette, Clarisse, Minenza, Elisa, Linardou, Helena, Burgers, Sjaak, Salman, Pamela, Borghaei, Hossein, Ramalingam, Suresh S., Brahmer, Julie, Reck, Martin, O’Byrne, Kenneth J., Geese, William J., Green, George, Chang, Han, Szustakowski, Joseph, Bhagavatheeswaran, Prabhu, Healey, Diane, Fu, Yali, Nathan, Faith, Paz-Ares, Luis·2018·New England Journal of Medicine

DOI 10.1056/nejmoa1801946PMC PMC7193684

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Nivolumab plus ipilimumab showed promising efficacy for the treatment of non-small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of benefit. In this part of an open-label, multipart, phase 3 trial, we examined progression-free survival with nivolumab plus ipilimumab versus chemotherapy among patients with a high tumor mutational burden (≥10 mutations per megabase). METHODS: We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy. Those with a level of tumor programmed death ligand 1 (PD-L1) expression of at least 1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab monotherapy, or chemotherapy; those with a tumor PD-L1 expression level of less than 1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy. Tumor mutational burden was determined by the FoundationOne CDx assay. RESULTS: Progression-free survival among patients with a high tumor mutational burden was significantly longer with nivolumab plus ipilimumab than with chemotherapy. The 1-year progression-free survival rate was 42.6% with nivolumab plus ipilimumab versus 13.2% with chemotherapy, and the median progression-free survival was 7.2 months (95% confidence interval [CI], 5.5 to 13.2) versus 5.5 months (95% CI, 4.4 to 5.8) (hazard ratio for disease progression or death, 0.58; 97.5% CI, 0.41 to 0.81; P<0.001). The objective response rate was 45.3% with nivolumab plus ipilimumab and 26.9% with chemotherapy. The benefit of nivolumab plus ipilimumab over chemotherapy was broadly consistent within subgroups, including patients with a PD-L1 expression level of at least 1% and those with a level of less than 1%. The rate of grade 3 or 4 treatment-related adverse events was 31.2% with nivolumab plus ipilimumab and 36.1% with chemotherapy. ical; CheckMate 227 ClinicalTrials.gov number, NCT02477826 .). CONCLUSIONS: Progression-free survival was significantly longer with first-line nivolumab plus ipilimumab than with chemotherapy among patients with NSCLC and a high tumor mutational burden, irrespective of PD-L1 expression level. The results validate the benefit of nivolumab plus ipilimumab in NSCLC and the role of tumor mutational burden as a biomarker for patient selection. (Funded by Bristol-Myers Squibb and Ono Pharmaceut

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1801946

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citation
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citation
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citation
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839

Flagged first, then by citations

Show all 22 references

Sorted by citations

Items 701–800 of 1,002

De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors
Workenhe, S. T., Nguyen, A., Bakhshinyan, D., Wei, J., Hare, D. N., MacNeill, K. L., Wan, Y., Oberst, A., Bramson, J. L., Nasir, J. A., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01362-w · Cited by 50
Targeting CTLA ‐4 in cancer: Is it the ideal companion for PD ‐1 blockade immunotherapy combinations?
Silva, P. D., Aiello, M. M., Gu‐Trantien, C., Migliori, E., Willard-Gallo, K. E., & Solinas, C. (2020) · International Journal of Cancer · doi:10.1002/ijc.33415 · Cited by 49
Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis
Zhao, Z., Wang, X., Qu, J., Zuo, W., Tang, Y., Zhu, H., & Chen, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.708195 · Cited by 49
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer
Ferrara, R., Imbimbo, M., Malouf, R. S., Paget‐Bailly, S., Calais, F., Marchal, C., & Westeel, V. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013257.pub2 · Cited by 51
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Sanmamed, M. F., Berraondo, P., Rodriguez-Ruiz, M. E., & Melero, I. (2022) · Nature Cancer · doi:10.1038/s43018-022-00401-1 · Cited by 50
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection
Banna, G. L., Passiglia, F., Colonese, F., Canova, S., Menis, J., Addeo, A., Russo, A. D., & Cortinovis, D. L. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.06.016 · Cited by 48
V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy
Zhou, X., Khan, S. H., Huang, D., & Li, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.938470 · Cited by 48
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
Gutierrez, M. E., Lam, W., Hellmann, M. D., Gubens, M. A., Aggarwal, C., Tan, D. S. W., Felip, E., Chiu, J. W. Y., Lee, J.-S., Yang, J. C.-H., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02385-6 · Cited by 49
Self-citation
Progresses in biomarkers for cancer immunotherapy
Lin, X., Zong, C., Zhang, Z., Fang, W., & Xu, P. (2023) · MedComm · doi:10.1002/mco2.387 · Cited by 50
Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond
Krichevsky, A. M., & Uhlmann, E. J. (2019) · Neurotherapeutics · doi:10.1007/s13311-018-00702-3 · Cited by 48
Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients
Hofman, V., Rouquette, I., Long-Mira, É., Piton, N., Chamorey, E., Heeke, S., Vignaud, J.-M., Yguel, C., Mazières, J., Page, A. L. L., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.024 · Cited by 48
Isolation and Identification of Cancer Stem-Like Cells in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Pilot Study
Masciale, V., Grisendi, G., Banchelli, F., D’Amico, R., Maiorana, A., Sighinolfi, P., Stefani, A., Morandi, U., Dominici, M., & Aramini, B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01394 · Cited by 48
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
Kyte, J. A., Andresen, N. K., Russnes, H., Fretland, S. Ø., Falk, R. S., Lingjærde, O. C., & Naume, B. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02421-w · Cited by 48
Progress in Neoantigen Targeted Cancer Immunotherapies
Han, X., Ma, X., Li, Y., Wei, Y.-Q., Peng, Y., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00728 · Cited by 49
Personalized Immuno-Oncology
Jain, K. K. (2020) · Medical Principles and Practice · doi:10.1159/000511107 · Cited by 53
Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non–Small Cell Lung Cancer
Wang, Z., Ying, J., Xu, J., Yuan, P., Duan, J., Bai, H., Guo, C., Li, L., Yang, Z., Wan, R., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.13770 · Cited by 48
Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance
Veluswamy, P., Wacker, M., Scherner, M. P., & Wippermann, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218159 · Cited by 49
Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial
Huang, X., He, M., Peng, H., Tong, C., Liu, Z., Zhang, X., Shao, Y. W., Zhu, D., Zhang, J., Yin, J. C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002223 · Cited by 48
Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response
Wu, M., Zhang, Y., Zhang, Y., Liu, Y., Wu, M., & Ye, Z. (2019) · Radiology Imaging Cancer · doi:10.1148/rycan.2019190031 · Cited by 47
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
Garassino, M. C., Gadgeel, S. M., Novello, S., Halmos, B., Felip, E., Speranza, G., Hui, R., Garon, E. B., Horinouchi, H., Sugawara, S., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100431 · Cited by 48
Self-citation
Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
Duan, J., Wang, Y., & Jiao, S. (2018) · Cancer Medicine · doi:10.1002/cam4.1722 · Cited by 47
Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy
Takada, K., Kohashi, K., Shimokawa, M., Haro, A., Osoegawa, A., Tagawa, T., Seto, T., Oda, Y., & Maehara, Y. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.12.008 · Cited by 46
Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis
Chakrabarti, R., Kapse, B., & Mukherjee, G. (2019) · Cancer Reports · doi:10.1002/cnr2.1160 · Cited by 46
Small lung tumor biopsy samples are feasible for high quality targeted next generation sequencing
Kage, H., Kohsaka, S., Shinozaki‐Ushiku, A., Hiraishi, Y., Sato, J., Nagayama, K., Ushiku, T., Takai, D., Nakajima, J., Miyagawa, K., et al. (2019) · Cancer Science · doi:10.1111/cas.14112 · Cited by 48
Possible Biomarkers for Cancer Immunotherapy
Otoshi, T., Nagano, T., TACHIHARA, M. Y., & Nishimura, Y. (2019) · Cancers · doi:10.3390/cancers11070935 · Cited by 47
Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms
Neuwelt, A. J., Kimball, A. K., Johnson, A. M., Arnold, B. W., Bullock, B., Kaspar, R. E., Kleczko, E. K., Kwak, J., Wu, M., Heasley, L. E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000441 · Cited by 46
Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis
Grover, S., Ruan, A. B., Srivoleti, P. D., Giobbie‐Hurder, A., Braschi‐Amirfarzan, M., Srivastava, A., Buchbinder, E. I., Ott, P. A., Kehl, K. L., Awad, M. M., et al. (2020) · JCO Oncology Practice · doi:10.1200/jop.19.00672 · Cited by 48
Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy
Niemeijer, A.-L. N., Sahba, S., Smit, E. F., Lissenberg-Witte, B. I., Langen, A. J. D., & Thunnissen, E. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0888-5 · Cited by 47
Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer
Le, X., Ferrarotto, R., Wise-Draper, T. M., & Gillison, M. L. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7590 · Cited by 47
Management of Advanced Penile Cancer
Chahoud, J., Kohli, M., & Spiess, P. E. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.06.031 · Cited by 47
Profiling of immune features to predict immunotherapy efficacy
Ye, Y., Zhang, Y., Yang, N., Gao, Q., Ding, X., Kuang, X., Bao, R., Zhang, Z., Sun, C., Zhou, B., et al. (2021) · The Innovation · doi:10.1016/j.xinn.2021.100194 · Cited by 46
The use of immunotherapy in older patients with advanced non-small cell lung cancer
Tagliamento, M., Frélaut, M., Baldini, C., Naigeon, M., Nencioni, A., Chaput, N., & Besse, B. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102394 · Cited by 48
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines
Passiglia, F., Pilotto, S., Facchinetti, F., Bertolaccini, L., Re, M. D., Ferrara, R., Franchina, T., Malapelle, U., Menis, J., Passaro, A., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102858 · Cited by 48
Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung
Santos, E. S., & Rodríguez, E. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.06.002 · Cited by 46
Immunotherapy in NSCLC Patients with Brain Metastases
Buriolla, S., Pelizzari, G., Corvaja, C., Alberti, M., Targato, G., Bortolot, M., Torresan, S., Cortiula, F., Fasola, G., & Follador, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137068 · Cited by 47
Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity
Mansouri, S., Heylmann, D., Stiewe, T., Kracht, M., & Savai, R. (2022) · eLife · doi:10.7554/elife.79895 · Cited by 45
Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers
Shi, F., Huang, X., Hong, Z., Lü, N., Huang, X., Liu, L., Liang, T., & Bai, X. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216167 · Cited by 46
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker
Signorelli, D., Giannatempo, P., Grazia, G., Aiello, M. M., Bertolini, F., Mirabile, A., Buti, S., Vasile, E., Scotti, V., Pisapia, P., et al. (2019) · BioMed Research International · doi:10.1155/2019/9056417 · Cited by 47
Use of Circulating Tumor DNA for Cancer Immunotherapy
Snyder, A., Morrissey, M., & Hellmann, M. D. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2688 · Cited by 48
Self-citation
The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer
Jain, R., Coss, C. C., Whooley, P. D., Phelps, M. A., & Owen, D. H. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00916-9 · Cited by 47
Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study
Cortellini, A., Giglio, A. D., Cannita, K., Cortinovis, D. L., Cornelissen, R., Baldessari, C., Giusti, R., D’Argento, E., Grossi, F., Santoni, M., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13852 · Cited by 46
Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker
Fountzilas, E., Kurzrock, R., Vo, H. H., & Tsimberidou, A. M. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab067 · Cited by 44
The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC
Li, X., Wang, Y., Li, X., Feng, G., Hu, S., & Bai, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.638763 · Cited by 46
Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
Xiong, W. G., Zhao, Y., Du, H., & Guo, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.704336 · Cited by 47
Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation
Elkrief, A., Waters, N. R., Smith, N., Dai, A., Slingerland, J., Aleynick, N., Febles, B., Gogia, P., Socci, N. D., Lumish, M., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0498 · Cited by 48
Self-citation
Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics
Louie, A. D., Huntington, K. E., Carlsen, L., Zhou, L., & El‐Deiry, W. S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.747194 · Cited by 46
Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions
Haddad, A. F., Young, J. S., Gill, S. A., & Aghi, M. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.019 · Cited by 47
Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab
Alban, T. J., Riaz, N., Parthasarathy, P. B., Makarov, V., Kendall, S. M., Yoo, S., Shah, R., Weinhold, N., Srivastava, R. M., Ma, X., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03240-y · Cited by 48
Self-citation
Immunotherapy in breast cancer: current landscape and emerging trends
Ran, R., Chen, X., Yang, J., & Xu, B. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00667-y · Cited by 60
Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients’ treatment
Onesti, C. E., Frères, P., & Jérusalem, G. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.47 · Cited by 46
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
Smith, K. N., Llosa, N. J., Cottrell, T. R., Siegel, N. M., Fan, H., Suri, P., Chan, H. Y., Guo, H., Oke, T. F., Awan, A. H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0492-x · Cited by 45
Self-citation
Immune-Related Adverse Events: A Case-Based Approach
Connolly, C. M., Bambhania, K., & Naidoo, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00530 · Cited by 46
Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns
Amaral, T. M. S., Osewold, M., Presser, D., Meiwes, A., Garbe, C., & Leiter, U. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15845 · Cited by 46
Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways
Bewersdorf, J. P., Shallis, R. M., & Zeidan, A. M. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100709 · Cited by 44
Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
Yan, X., Tian, X., Wu, Z., & Han, W. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01671 · Cited by 45
Landscape of immune checkpoint inhibitor-related adverse events in Chinese population
Li, L., Li, G., Rao, B., Dong, A.-H., Liang, W., Zhu, J., Qin, M.-P., Huang, W., Lu, J., Li, Z.-F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72649-5 · Cited by 46
Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution
Kleef, R., Nagy, R., Baierl, A., Bacher, V., Bojar, H., McKee, D. L., Moss, R. W., Thoennissen, N. H., Szász, A. M., & Bakács, T. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02751-0 · Cited by 46
LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma
Wang, L., Yan, K., He, X., Zhu, H., Song, J., Chen, S., Cai, S., Zhao, Y., & Wang, L. (2020) · Journal of Cancer · doi:10.7150/jca.48983 · Cited by 43
Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study
Nadler, E., Arondekar, B. V., Aguilar, K. M., Zhou, J., Chang, J., Zhang, X., & Pawar, V. S. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03414-4 · Cited by 48
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study
Calabrò, L., Rossi, G., Morra, A., Rosati, C., Cutaia, O., Daffinà, M. G., Altomonte, M., Giacomo, A. M. D., Casula, M., Fazio, C., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00043-6 · Cited by 45
Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer
Berti, A., Bortolotti, R., Dipasquale, M., Kinspergher, S., Prokop, L. J., Grandi, G., Inchiostro, S., Paolazzi, G., Caffo, O., & Veccia, A. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103351 · Cited by 49
33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)
Golinelli, G., Dominici, M., Grisendi, G., Spano, C., Rossignoli, F., & Prapa, M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0422-y · Cited by 45
Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment—are we barking up the wrong tree?
Dempke, W. C. M., Fenchel, K., & Dale, S. P. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.04.18 · Cited by 46
First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2 -altered NSCLC: a retrospective real-world POLISH study
Yang, G., Yang, Y., Liu, R., Li, W., Xu, H., Hao, X., Li, J., Xing, P., Zhang, S., Ai, X., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221082339 · Cited by 44
Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials
Zhang, Z., Pan, Q., Lu, M., & Zhao, B. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102156 · Cited by 46
Prognostic and predictive biomarkers in non-small cell lung carcinoma
Odintsov, I., & Sholl, L. M. (2023) · Pathology · doi:10.1016/j.pathol.2023.11.006 · Cited by 47
Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients
Mei, T., Wang, T., & Zhou, Q. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01324-0 · Cited by 47
Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison
Cheng, L., Chen, L., Shi, Y., Gu, W., Ding, W., Zheng, X. W., Liu, Y., Jiang, J., & Zheng, Z. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01956-6 · Cited by 49
Polymeric Nanoparticles for Targeted Lung Cancer Treatment: Review and Perspectives
Kapoor, D. U., Gandhi, S. M., Swarn, S., Lal, B., Prajapati, B. G., Khondee, S., Mangmool, S., Singh, S. K., & Chittasupho, C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091091 · Cited by 48
Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
Hierro, C., Matos, I. G., Martín-Liberal, J., de Olza, M. O., & Garralda, E. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3694 · Cited by 44
Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors
Sanghavi, K., Zhang, J. Y., Zhao, X., Feng, Y., Statkevich, P., Sheng, J., Roy, A., & Vezina, H. E. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12477 · Cited by 44
Current and potential immunohistochemical biomarkers for prognosis and therapeutic stratification of breast carcinoma
Ronchi, A., Pagliuca, F., Marino, F. Z., Accardo, M., Cozzolino, I., & Franco, R. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.002 · Cited by 44
Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
Chen, X., Zhang, Z., Hou, X., Zhang, Y., Zhou, T., Liu, J., Lin, Z., Fang, W., Yang, Y., Ma, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001170 · Cited by 44
Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44
Cummings, A. L., Gukasyan, J., Lu, H. Y., Grogan, T., Sunga, G. M., Fares, C. M., Hornstein, N. J., Zaretsky, J. M., Carroll, J., Bachrach, B., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00140-1 · Cited by 46
CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC
Leighl, N. B., Laurie, S. A., Goss, G. D., Hughes, B. G. M., Stockler, M. R., Tsao, M., Hwang, D. M., Joubert, P., Kulkarni, S., Blais, N., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.023 · Cited by 47
Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer
Lee, Y. J., Park, Y. S., Lee, H. W., Park, T. Y., Lee, J., & Heo, E. Y. (2022) · Scientific Reports · doi:10.1038/s41598-021-04630-9 · Cited by 46
Self-citation
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
Tai, D. W.-M., Choo, S. P., & Chew, V. (2019) · Cancers · doi:10.3390/cancers11121926 · Cited by 43
Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing
Heydt, C., Rehker, J., Pappesch, R., Buhl, T., Ball, M., Siebolts, U., Haak, A., Lohneis, P., Büttner, R., Hillmer, A. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-68394-4 · Cited by 44
Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
Harel, M., Lahav, C., Jacob, E., Dahan, N., Sela, I., Elon, Y., Raveh, S., Yahalom, G., Kamer, I., Zer, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004582 · Cited by 43
Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data
So, W. V., Dejardin, D., Rossmann, E. D., & Charo, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006464 · Cited by 45
Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small–cell lung cancer (ES-SCLC): a phase II trial
Chen, D., Zou, B., Li, B., Gao, A., Huang, W., Shao, Q., Meng, X., Zhang, P., Tang, X., Hu, X., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102795 · Cited by 43
Biomarkers for immunotherapy resistance in non-small cell lung cancer
Rother, C., John, T., & Wong, A. N. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1489977 · Cited by 46
The tumor immune microenvironment: implications for cancer immunotherapy, treatment strategies, and monitoring approaches
Racacho, K. J., Shiau, Y., Villa, R., Mahri, S., Tang, M., Lin, T., & Li, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1621812 · Cited by 55
Expert opinion on thyroid complications in immunotherapy
Illouz, F., Drui, D., Caron, P. J., & Cao, C. D. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.07.007 · Cited by 44
A Comparison of Outcomes and Prognostic Features for Radiation-Associated Angiosarcoma of the Breast and Other Radiation-Associated Sarcomas
Mito, J. K., Mitra, D., Barysauskas, C. M., Mariño‐Enríquez, A., Morgan, E. A., Fletcher, C. D. �., Raut, C. P., Baldini, E. H., & Doyle, L. A. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.01.082 · Cited by 43
Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy
Singh, S. S., Dahal, A., Shrestha, L., & Jois, S. D. S. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190222183219 · Cited by 42
Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies
Puri, S., & Shafique, M. R. (2020) · Drugs in Context · doi:10.7573/dic.2019-9-2 · Cited by 44
Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
Friedlaender, A., Nouspikel, T., Christinat, Y., Ho, L. K. F., McKee, T., & Addeo, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00142 · Cited by 44
Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors
Sun, J., Zheng, Y., Mamun, M., Li, X., Chen, X., & Gao, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110504 · Cited by 44
Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
Hu, H., She, L., Liao, M., Shi, Y., Yao, L., Ding, D., Zhu, Y., Zeng, S., Carbone, D. P., & Huang, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01649 · Cited by 43
Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer
Li, S., Zhang, C., Pang, G., & Wang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.603157 · Cited by 43
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1
Reck, M., Ciuleanu, T., Lee, J.-S., Schenker, M., Audigier-Valette, C., Żurawski, B. A., Linardou, H., Otterson, G. A., Salman, P., Nishio, M., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.019 · Cited by 43
Self-citation
Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment
Zhao, Y., Zhang, M., Pu, H., Guo, S., Zhang, S., & Wang, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.585961 · Cited by 41
Multi-omics analysis reveals prognostic value of tumor mutation burden in hepatocellular carcinoma
Xu, Q., Xu, H., Deng, R., Wang, Z., Li, N., Qi, Z., Zhao, J., & Huang, W. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02049-w · Cited by 43
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
Friedman, C. F., Spencer, C. N., Cabanski, C. R., Panageas, K. S., Wells, D. K., Ribas, A., Tawbi, H. A., Tsai, K. K., Postow, M. A., Shoushtari, A. N., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003853 · Cited by 47
Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience
Bhatlapenumarthi, V., Patwari, A., & Harb, A. J. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03610-w · Cited by 42
Reprogramming NK Cells and Macrophages via Combined Antibody and Cytokine Therapy Primes Tumors for Elimination by Checkpoint Blockade
Wang, C., Cui, A., Bukenya, M., Aung, A., Pradhan, D., Whittaker, C. A., Agarwal, Y., Thomas, A., Liang, S., Amlashi, P., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110021 · Cited by 43
A Novel Classification Model for Lower-Grade Glioma Patients Based on Pyroptosis-Related Genes
Shen, Y., Chi, H., Xu, K., Li, Y., Yin, X., Chen, S., Yang, Q., He, M., Zhu, G., & Li, X. (2022) · Brain Sciences · doi:10.3390/brainsci12060700 · Cited by 43
Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment?
Putzu, C., Canova, S., Paliogiannis, P., Lobrano, R., Sala, L., Cortinovis, D. L., & Colonese, F. (2023) · Cancers · doi:10.3390/cancers15030689 · Cited by 42
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC
Alessi, J. V., Wang, X., Elkrief, A., Ricciuti, B., Li, Y. Y., Gupta, H. V., Spurr, L. F., Rizvi, H. A., Luo, J., Pecci, F., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.05.019 · Cited by 42

Authors: Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., Borghaei, H., Ramalingam, S. S., Brahmer, J., Reck, M., O’Byrne, K. J., Geese, W. J., Green, G., Chang, H., Szustakowski, J., Bhagavatheeswaran, P., Healey, D., Fu, Y., Nathan, F., & Paz-Ares, L.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
From Memorial Sloan Kettering Cancer Center Hospital, New York (M.D.H.); Prof. Dr. Ion Chiricuta Institute of Oncology and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.); Centrum Onkologii–Instytut im. Marii Sklodowskiej-Curie, Warsaw, Poland (A.P.); Seoul National University Bundang Hospital, Seoul, South Korea (J.S.L.); Ohio State University, Columbus (G.A.O.); Hôpital Sainte Musse, Toulon, France (C.A.-V.); Ospedale Santa Maria della Misericordia, Perugia,...
Fox Chase Cancer Center (US)
ORCID: Hellmann, Matthew D.
Ciuleanu, Tudor-Eliade
Lee, Jong Seok
Otterson, Gregory A.
Audigier-Valette, Clarisse
Linardou, Helena
Burgers, Sjaak
Salman, Pamela
Borghaei, Hossein
Ramalingam, Suresh S.
Brahmer, Julie
Reck, Martin
Geese, William J.
Green, George
Szustakowski, Joseph
Fu, Yali
Paz-Ares, Luis
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2018-05-31
Volume: 378
Issue: 22
Pages: 2093-2104
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1801946
PMC: PMC7193684
OpenAlex: W2797675588
Cited by: 3,063
References: 22
Citations by year: 2026: 100 · 2025: 184 · 2024: 222 · 2023: 289 · 2022: 419 · 2021: 499 · 2020: 559 · 2019: 542 · 2018: 247
FWCI: 174.31
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Bristol-Myers Squibb, Inc.
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: nivolumab, ipilimumab, non-small cell lung cancer, tumor mutational burden, PD-L1 expression, immune checkpoint inhibitors, progression-free survival, chemotherapy comparison, stage IV lung cancer, treatment-related adverse events, treatment response biomarkers, objective response rate, immunotherapy biomarkers, safety and tolerability
MeSH terms: Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Biomarkers, Tumor, Disease-Free Survival, Kaplan-Meier Estimate, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks